Target Audience
PM-M04_01: General Concepts in TB Treatment
- Strategies for TB Treatment
- Pharmacological Basis of treatment
- Treatment Phases
- FDCs used in NTEP
- First line anti TB drugs
- Second Line anti TB drugs
- Types of Drug Resistance Tuberculosis -DRTB
- TB Drug Regimen
- TB Treatment Initiation
- Pre-treatment Evaluation of TB patients
- Start Treatment for DSTB patient & DRTB patient
- Follow-up of TB patient
- Follow-up sputum examination
- Nikshay - Drug Dispensation Module
- Adding and viewing Patient Notes
- Assigning Patients to ART and DRTB Centres
- Updating and Viewing patient Health Facility details
- TB Treatment Outcome
- Closing Cases and Assigning Treatment Outcomes
- Long Term Post-treatment follow up of TB patients
- Reinitiating case
- Active TB Drug Safety Monitoring [aDSM]
- Transfer of TB Patient Ownership
- Transferring a patient
PM-M04_02: DS-TB Treatment and Care
PM-M04_03: Overview of DR-TB Treatment and care
- DR-TB Centres and Network
- DR-TB Treatment Regimens
- Adverse Drug Reactions(ADRs) to Second Line Treatment
- Manage TB India Application
- Pre-treatment Counselling
- Pre treatment evaluation of DRTB cases
- Interim Treatment Outcomes of DR-TB Cases
- Final Treatment Outcomes of DR-TB Cases
- Follow-up Monitoring of DR-TB Patients
- Follow up sputum examination for DR-TB
PM-M04_04: Isoniazid [H] Mono/Poly DR-TB Regimen
- Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation
- Eligibility Criteria for H Mono/poly DR-TB Regimen
- Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen
- Replacement Sequence in the H Mono/Poly DR-TB
- Follow up sputum examination for Isoniazid [H] Mono/Poly DR-TB Regimen
PM-M04_05: Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE]
- Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment
- Shorter oral Bedaquiline-containing MDR/RR-TB regimen
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Dosage of Drugs for Adults
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Replacement Sequence of Drugs
- Follow up sputum examination for Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
PM-M04_06: Longer Oral M/XDR-TB Regimen
- Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen
- Eligibility Criteria for Longer Oral M/XDR-TB Regimen
- Longer Oral M/XDR-TB: Regimen and Duration
- Treatment Extension in Longer Oral M/XDR-TB Regimen
- Dosages of M/XDR-TB Drugs for Adult in Longer Oral M/XDR-TB Regimen
- Details of Replacement Sequence of Drugs in Longer Oral M/XDR-TB Regimen
- Follow up sputum examination for Longer Oral M/XDR-TB DR-TB Regimen
PM-M04_07: Treatment Support and Adherence Management
- Treatment Support Mechanism
- Treatment Support Plan
- Patient-Provider Meetings
- Treatment supporter to TB Patient
- Assigning a TS
- Treatment Support Groups
- Teleconsultation for treatment support
- TB Treatment Adherence
- Importance of Treatment adherence
- Recording and Monitoring Adherence
- Digital Adherence Monitoring Technologies
- Directly Observed Treatment
- Recording Adherence in Treatment card
- Recording manual doses in Ni-kshay
- Recording missed doses in Ni-kshay
- Recording Adherence using TB Arogya Sathi Application
- Monitoring of Adherence by NTEP Staff
- Monitoring of Adherence by Pateint/TS
- Management of Patients with Treatment Interruptions
- Adherence Summary Dashboard
- Patient Adherence Dashboard
PM-M04_09: ADRs to ATT
- Adverse Drug Reactions
- Types of ADR of TB Treatment
- Management of Adverse Drug Reactions(ADRs) of TB Treatment
- Active TB Drug Safety Monitoring [aDSM]
- Pharmacovigilance in NTEP
- Possible Adverse Events Due to Drugs in Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen
- Adverse Drug Events: H Mono/Poly DR-TB Regimen
- Adverse Drug Reactions(ADRs) to Second Line Treatment
PM-M04_10: Monitoring of Treatment
- Monitoring indicator for TB Treatment outcome
- Monitoring indicators related to DR-TB Treatment
- NTEP Performance Indicator - Treatment Success Rate
- NTEP Performance Indicator – Percentage Of Multidrug-resistant (MDR)/ Rifampicin-resistant (RR) Patients Initiated on Treatment Out of Totally Diagnosed
- RCA for low performance in in Percentage Treatment initiation of RR/MDR-TB Cases
- DRTB Treatment Register
- Prescription Register
- Follow-Up Register
- DRTB Follow Up Register
Cover
Cover!